ERR1 and PGC1α associated mitochondrial alterations correlate with pan-cancer disparity in African Americans.

BACKGROUND African American (AA) patients have higher cancer mortality rates and shorter survival times compared to European American (EA) patients. Despite a significant focus on socioeconomic factors, recent findings strongly argue the existence of biological factors driving this disparity. Most of these factors have been described in a cancer-type specific context rather than a pan-cancer setting. METHODS A novel in silico approach based on Gene Set Enrichment Analysis (GSEA) coupled to Transcription Factor enrichment was carried out to identify common biological drivers of pan-cancer racial disparity using The Cancer Genome Atlas (TCGA) dataset. Mitochondrial content in patient tissues was examined using a multi-cancer tissue microarray approach (TMA). RESULTS Mitochondrial oxidative phosphorylation was uniquely enriched in AA tumors compared to EA tumors across various cancer types. AA tumors also showed strong enrichment for the ERR1-PGC1α-mediated transcriptional program, which has been implicated in mitochondrial biogenesis. TMA analysis revealed that AA cancers harbor significantly more mitochondria compared to their EA counterparts. CONCLUSIONS These findings highlight changes in mitochondria as a common distinguishing feature between AA and EA tumors in a pan-cancer setting, and provide the rationale for the repurposing of mitochondrial inhibitors to treat AA cancers.

[1]  M. Stern,et al.  Mitochondrial biology and prostate cancer ethnic disparity , 2018, Carcinogenesis.

[2]  M. Salifu,et al.  Survival benefits in colorectal adenocarcinoma with the use of metformin among a black diabetic inner city population. , 2017, Colorectal cancer.

[3]  F. Deng,et al.  Molecular mechanisms involving prostate cancer racial disparity. , 2017, American journal of clinical and experimental urology.

[4]  Jeff S. Jasper,et al.  ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer. , 2016, Cell reports.

[5]  E. Bowman,et al.  Differential Serum Cytokine Levels and Risk of Lung Cancer Between African and European Americans , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[6]  G. Andriole,et al.  Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study , 2015, Cancer Prevention Research.

[7]  O. Olopade,et al.  A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change , 2015, CA: a cancer journal for clinicians.

[8]  T. Bethea,et al.  Health Disparities and Cancer: Racial Disparities in Cancer Mortality in the United States, 2000–2010 , 2015, Front. Public Health.

[9]  A. Singh,et al.  Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation , 2015, Oncotarget.

[10]  Bei-fang Ning,et al.  Abstract 134: HNF4α inhibits liver cancer metastasis via suppression of NF-кB activity , 2014 .

[11]  L. Williams,et al.  Differing effects of metformin on glycemic control by race-ethnicity. , 2014, The Journal of clinical endocrinology and metabolism.

[12]  Sarah J. Kurley,et al.  MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. , 2014, The Journal of clinical investigation.

[13]  Z. A. Abd Elmageed,et al.  High circulating estrogens and selective expression of ERβ in prostate tumors of Americans: implications for racial disparity of prostate cancer. , 2013, Carcinogenesis.

[14]  S. Ambs,et al.  Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. , 2011, Carcinogenesis.

[15]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[16]  A. Jemal,et al.  Global Patterns of Cancer Incidence and Mortality Rates and Trends , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[17]  A. Jemal,et al.  The global burden of cancer: priorities for prevention , 2009, Carcinogenesis.

[18]  I. Osman,et al.  Molecular mechanisms involving prostate cancer racial disparity. , 2009, American journal of translational research.

[19]  I. Powell Epidemiology and pathophysiology of prostate cancer in African-American men. , 2007, The Journal of urology.

[20]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Bartek,et al.  Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. , 2004, DNA repair.

[23]  Charles L. Hoppel,et al.  Production of Reactive Oxygen Species by Mitochondria , 2003, Journal of Biological Chemistry.

[24]  F. Mostofi,et al.  Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. , 1995, JAMA.

[25]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .